CD22 and neoplasm: CAR-Ms have been reported to target CD19, CD22, and HER2 on tumor cells for tumor clearance (Morrissey et al., 2018; Zhang et al., 2020; Zhang et al., 2019), and there are also reports indicating that they target the FAP protein for the treatment of liver fibrosis (Kim and Seki, 2023; Wegrzyniak et al., 2021; Yang AT.